Group 1 - The article does not provide any specific content related to a company or industry [1]

Financial Data and Key Metrics Changes - The company reported revenue of $206 million for Q3 2025, a decrease of 4% year-over-year, but a 5% growth when excluding specific headwinds [4][24][26] - Adjusted gross margin was strong at 70.1%, with adjusted EBITDA reported at $10.3 million [6][28] - Test volumes increased by 3%, but average revenue per test decreased by 7% [23][24] Business Line Data and Key Metrics Changes - Oncology revenue was $81.8 million, a decline of 1% year-over-year, with myRisk test volume growth of 16% in the affected market and 11% in the unaffected market [15][19] - Women's health revenue increased by 3% to $85.2 million, with hereditary cancer testing showing a 4% revenue growth and 11% volume growth year-over-year [19][20] - GeneSight revenue was $38.7 million, with an 8% volume growth year-over-year, despite challenges from UnitedHealthcare's coverage policy change [21][22] Market Data and Key Metrics Changes - The hereditary cancer testing market is estimated to be close to $5 billion, with less than 50% penetration, indicating significant growth opportunities [55] - The company is experiencing positive momentum in prenatal testing, with expectations for continued growth following the introduction of the FirstGene test [20][21] Company Strategy and Development Direction - The company is focusing on the cancer care continuum to accelerate growth, leveraging the myRisk test and expanding its portfolio to include other cancer screening and diagnostic tests [7][8] - There is a commitment to grow prenatal health and mental health revenues at or above market growth, with a disciplined investment approach [8][12] - The company is enhancing its commercial capabilities and organizational design to improve customer experience and market share [11][12][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver accelerated profitable growth, emphasizing the importance of operational efficiency and strategic partnerships [9][10][11] - The company is optimistic about the upcoming launches of new products, including an updated myRisk test and the Prolaris prostate cancer test [10][11][18] Other Important Information - The company reaffirmed its full-year 2025 financial guidance, projecting revenue between $818 million and $828 million [30] - The organizational redesign aims to reduce management layers and improve efficiency, which is expected to support revenue growth while controlling operating expenses [29][30] Q&A Session Summary Question: What are the offsets in savings as you go into 2026? - Management reaffirmed a commitment to profitable growth, focusing on the cancer care continuum and reallocating investments to support growth while managing operating expenses [36][37] Question: Any share shift in the NIPT market? - Management acknowledged challenges in operational execution but indicated improvements are being made, with expectations for future growth driven by new products [40][41] Question: Can you provide color on the friction with the new ordering management system? - Management noted that regaining customer volume takes time, but improvements are being made, and they expect to show volume growth in the coming quarters [44][45] Question: What is the current average turnaround time for Prequel results? - Management stated that turnaround times for their products are competitive, emphasizing patient convenience and workflow improvements [68][69] Question: How should we think about ASP assumptions for 2026? - Management highlighted that ASP was impacted by several factors, including changes in payer mix and the divestiture of the EndoPredict business, but they expect positive trends to continue [63][64]

Financial Performance - Q3 2025 revenue was $205.7 million[7], a decrease of 4% year-over-year[33] - Adjusted gross margin in Q3 2025 was 70.1%[7], a decrease of 50 basis points year-over-year[33] - Adjusted EBITDA for Q3 2025 was $10.3 million[7] - Adjusted EPS for Q3 2025 was $0.00[7], a decrease of $0.06 year-over-year[33] - Adjusted operating expenses decreased by $1 million year-over-year in Q3 2025[7] Volume Growth - Hereditary cancer test volume grew 11% year-over-year[8] - GeneSight volume grew 8% year-over-year[8], reflecting ongoing growth acceleration from Q1 '25[30] - Prolaris test volume showed positive growth year-over-year[8] Strategic Initiatives - The company is focused on the Cancer Care Continuum (CCC) to accelerate growth[7, 9, 11] - The company aims to grow revenue at or above market in Prenatal Health and Mental Health[7, 9, 12] - Myriad has commenced a multi-year program to invest >$35 million in its commercial capabilities addressing the Cancer Care Continuum[40] 2025 Financial Guidance - The company reiterates its 2025 financial guidance, with total revenue expected to be between $818 million and $828 million[42] - Gross margin is projected to be between 69.5% and 70.0%[42] - Adjusted operating expenses are expected to be between $562 million and $568 million[42] - Adjusted EBITDA is projected to be between $27 million and $33 million[42] - Adjusted EPS is expected to be between $(0.02) and $0.02[42]

Exhibit 99.1 Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution Highlights SALT LAKE CITY, November 3, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2025 and reaffirmed its financial guidance on business performance for the full-year 2025. "I am pleased with our solid results for the quart ...

Core Insights - Myriad Genetics reported third-quarter 2025 financial results, showing stable revenue performance and a 13% year-over-year volume growth for its MyRisk hereditary cancer test [2][3]. Financial Performance - Third-quarter 2025 revenue was $205.7 million, a decrease of 4% year-over-year, but flat when excluding headwinds of $8.1 million [5][7]. - The gross margin for the third quarter was 69.9% [5]. - The company reported a GAAP net loss of $27.4 million, or $0.29 per share, while adjusted EPS was $0.00 [5][12]. - Adjusted EBITDA for the third quarter was $10.3 million [5]. Product Volumes and Revenue - Total product volumes for the third quarter were 386,000, reflecting a 3% year-over-year increase [6]. - Hereditary cancer testing revenue grew 3% year-over-year to $93.0 million, with volume increasing by 11% [7][11]. - Tumor profiling revenue decreased by 7% year-over-year to $29.5 million, primarily due to a decline in testing volume for EndoPredict [7][12]. - Prenatal testing revenue increased by 2% year-over-year to $44.5 million, while pharmacogenomics revenue decreased by 19% to $38.7 million [7][14]. Cash Flow and Liquidity - Cash flow from operations for the third quarter was $21.1 million, with adjusted operating cash flow at $24.8 million [8]. - As of September 30, 2025, the company had cash and cash equivalents of $145.4 million [9]. Strategic Initiatives - The company entered a strategic collaboration with SOPHiA GENETICS to develop a global liquid biopsy companion diagnostic testing solution for pharmaceutical companies [5][13]. - Myriad Genetics is focusing on the Cancer Care Continuum and has made organizational changes to improve customer experience and reduce operating expenses [3][12]. Financial Guidance - The company reaffirmed its full-year 2025 revenue guidance in the range of $818 million to $828 million, with expected gross margins between 69.5% and 70.0% [16]. - Adjusted EBITDA guidance remains unchanged at $27 million to $33 million [16].

Core Insights - Myriad Genetics announced that treatment informed by the GeneSight test resulted in faster initial remission and response in patients with Major Depressive Disorder (MDD), with benefits persisting over six months [1][2][3] Group 1: Study Overview - The PRIME Care study is the largest pharmacogenomic randomized controlled trial in mental health, enrolling 1,944 U.S. Veterans with depression to assess the impact of GeneSight results on treatment outcomes [2][4] - The study found that patients whose clinicians had GeneSight results were significantly more likely to achieve remission over 24 weeks, with a 28% higher likelihood compared to the usual care group [5][6] Group 2: Post-Hoc Analysis Findings - The post-hoc analysis included 1,764 veterans and focused on the time to first remission and response, showing that GeneSight test results increased the rate of remission and response over time [3][6] - Patients who took the GeneSight test were 27% more likely to achieve remission and 21% more likely to experience a significant reduction in depressive symptoms [8] Group 3: GeneSight Test Information - The GeneSight Psychotropic test is a leading pharmacogenomic test for over 60 medications commonly prescribed for mental health conditions, aimed at reducing the trial-and-error process in medication prescribing [7][8] Group 4: Company Background - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, dedicated to advancing health and well-being through molecular tests that guide treatment decisions across various medical specialties [8][9]

Core Viewpoint - Myriad Genetics, Inc. will hold its third quarter 2025 earnings conference call on November 3, 2025, at 4:30 pm ET, with earnings released after market close on the same day [1]. Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, focusing on advancing health and well-being through molecular tests that assess disease risk and guide treatment decisions [3]. Conference Call Details - The conference call will provide a financial overview and business update regarding the company's performance for the third quarter of 2025 [1]. - A live webcast of the conference call will be available on Myriad's Investor Relations website, and an archived version will be accessible after the call [2].

Core Insights - Myriad Genetics has added two genes, F8 and FXN, to its Foresight Carrier Screen Universal Plus Panel, enhancing its compliance with the American College of Medical Genetics and Genomics recommendations [1][4]. Gene-Specific Information - Variants in the F8 gene are associated with hemophilia A, a hereditary bleeding disorder that can lead to prolonged bleeding [2]. - The FXN gene is linked to Friedreich's ataxia, a rare neurodegenerative disease that causes motor weakness and sensory loss [3]. Product Features and Impact - The Foresight Carrier Screen is designed to provide vital genetic insights for informed family planning, with a detection rate of one in 22 couples for serious inherited conditions [6]. - The Foresight Carrier Screen has been validated through over 20 peer-reviewed publications and is the only expanded carrier screening test with published analytical validation in the US [5]. Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, focusing on improving patient care and reducing healthcare costs through molecular insights [7].

Core Insights - A recent survey by Myriad Genetics reveals a significant contradiction in women's attitudes towards cancer screenings, with 80% expressing fear of screenings, yet 75% indicating that genetic testing would provide reassurance if facing health concerns [2][3] - The survey highlights a critical gap in awareness regarding advanced screening tools that could empower women, especially those at increased risk for hereditary cancers [2] Group 1: Survey Findings - More than half of women at high risk for hereditary cancer feel "empowered" by advanced screening options like genetic testing [1] - Approximately 40% of women surveyed were unaware of the existence of genetic testing tools to assess personal cancer risk [3] - Only 14% of respondents have undergone genetic testing, despite over 25% of women in an OB/GYN setting meeting criteria for hereditary cancer testing [3] Group 2: Importance of Family Health History - Over 50% of respondents believe knowing their parents' health history is very important, but only about 30% reported knowing it "very well" [4] - About 48% of respondents would encourage their younger selves to discuss health history more frequently with their parents [4] Group 3: Genetic Testing and Risk Management - The MyRisk Hereditary Cancer Test with RiskScore calculates a woman's five-year and lifetime risk of breast cancer, providing options for increased screening frequency if high risk is identified [6] - Understanding familial factors, such as multiple cancers in the family and the age of diagnosis, is crucial for determining the need for hereditary cancer testing [5]

Core Insights - Myriad Genetics and SOPHiA GENETICS have announced a strategic collaboration to develop a global liquid biopsy companion diagnostic test for pharmaceutical companies [1] Company Overview - Myriad Genetics is recognized as a leader in molecular diagnostic testing and precision medicine [1] - SOPHiA GENETICS is an AI technology company focused on transforming precision medicine [1] Collaboration Details - The collaboration aims to innovate and provide pharmaceutical companies with advanced diagnostic solutions [1]